April 25th 2024
In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity
December 21st 2017Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.
Watch
Conference Stories That Captivated AJMC® Readers in 2017
December 21st 2017In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.
Read More
Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity
December 21st 2017Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Watch
As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?
December 18th 2017Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
Read More
Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes
December 5th 2017On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.
Watch
Dr Eliot A. Brinton: Perspectives on PCSK9 Inhibitors
December 1st 2017Results from the FOURIER trial have provided convincing data that there is no downside to aggressively lowering cholesterol with PCSK9 inhibitors, and studies have shown there are cardiovascular benefits associated with Repatha, but reimbursement remains challenging, said Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
Watch
Any Physical Activity Lowers CVD Risk for Elderly, Study Finds
November 29th 2017Physical activity, even of a low-intensity, reduces the risk of cardiovascular disease in older adults, according to a study published in The European Journal of Preventive Cardiology. Although the authors found similar associations for individuals under age 55 and individuals aged 55-65, the results were not statistically significant.
Read More
Systolic Blood Pressure of 140 mm Hg or Higher Should Be Treated to Prevent Death and CVD
November 23rd 2017A study published in JAMA Internal Medicine found that blood pressure (BP) lowering is associated with reduced risk of death and cardiovascular disease (CVD) if the baseline systolic blood pressure (SBP) is 140 mm Hg or higher. Treatment may be considered in patients with coronary heart disease and SBP under 140 mm Hg, but not for primary prevention.
Read More
Dr Justin Bachmann: Challenges of Implementing Behavioral Interventions in Cardiac Care
November 18th 2017The biggest challenge of implementing behavioral interventions to improve care for patients with cardiovascular disease is reimbursement models, said Justin Bachmann, MD, MPH, FACC, Cardiologist and Clinical Investigator, Instructor of Medicine and Health Policy, Vanderbilt University Medical Center.
Watch
Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation
November 9th 2017Digital health, artificial intelligence and machine learning, and precision medicine are the areas where there is the most excitement in innovations for cardiovascular care, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
Watch
Rheumatology Patients at Increased Risk for Cardiac Disease
November 7th 2017During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.
Read More
Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies
November 4th 2017The biggest challenges in promoting cardiovascular prevention strategies is motivating people to change a lifetime of poor habits into healthier habits, explained Christi Deaton, PhD, RN, FAHA, FESC, of the University of Cambridge.
Watch
Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine
October 24th 2017The digital transformation of the cardiology field in the coming years will have a huge impact on the delivery of healthcare, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
Watch